Evaluation of three commercial rapid immunoassays for the diagnosis of Clostridioides difficile infection
Microbiology Spectrum · 2025
DOI: 10.1128/spectrum.03405-24 ↗Kurz gefasst
Evaluationsstudie in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Hannes Bjarki Vigfússon und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, Clinical Microbiology, The Swedish Reference Laboratory for Clostridioides difficile, Örebro University Hospital, …. Hauptthemen laut MEDLINE: Clostridioides difficile, Clostridium Infections. Die Arbeit nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Current guidelines recommend the use of a two-step algorithm for the laboratory diagnosis of Clostridioides difficile infection (CDI). Several commercial rapid immunoassays that detect both GDH and toxin A/B in stool samples are available and could be used for both steps of the diagnostic algorithm. We aimed to evaluate the performance of three of these rapid immunoassays and study pathogen characteristics that might affect the sensitivity of toxin A/B detection. Leftover material from routinely collected stool samples from patients suspected of CDI was analyzed with the three immunoassays, nucleic acid amplification test (NAAT), and culture. Whole-genome sequencing was then used to evaluate C. difficile isolates recovered from the samples. The positive percent agreement between GDH detection and detection of tcdA by NAAT was 100% with all three immunoassays. The positive percent agreement for the detection of toxin A/B, however, was considerably lower (50.0%, 51.7%, and 71.4%), and freezing stool samples seemed to negatively affect the detection of both GDH and toxins. The isolates included in the study belonged to 23 different sequence types (ST) and all carried the tcdA and tcdB genes. The C. diff Quik Chek Complete performed the best of the three immunoassays, and when used in combination with NAAT, is a viable option for the laboratory diagnosis of CDI. IMPORTANCE Laboratory diagnosis of Clostridioides difficile infection is complex, and current guidelines recommend a two-step diagnostic algorithm with a sensitive screening test and a more specific confirmatory test. The study aimed to evaluate three commercial rapid immunoassays that detect both glutamate dehydrogenase (GDH) and toxins A and B. These tests could be used for both steps of the two-step diagnostic algorithm and facilitate rapid laboratory confirmation of CDI, which is important for clinical decision-making and infection control measures.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, Clinical Microbiology, The Swedish Reference Laboratory for Clostridioides difficile, Örebro University Hospital, Örebro, Sweden.
- Faculty of Medicine and Health, Örebro University, Örebro, Sweden.
ORCID-Profile: Hannes Bjarki Vigfússon
Zitieren
APA
Vigfússon, H. B., Ennefors, T., Norén, T., & Sundqvist, M. (2025). Evaluation of three commercial rapid immunoassays for the diagnosis of Clostridioides difficile infection. Microbiology Spectrum. https://doi.org/10.1128/spectrum.03405-24
Vancouver
Vigfússon HB, Ennefors T, Norén T, Sundqvist M. Evaluation of three commercial rapid immunoassays for the diagnosis of Clostridioides difficile infection. Microbiology Spectrum. 2025. doi:10.1128/spectrum.03405-24
BibTeX
@article{Vigfsson2025,
author = {Vigfússon, Hannes Bjarki and Ennefors, Theresa and Norén, Torbjörn and Sundqvist, Martin},
title = {Evaluation of three commercial rapid immunoassays for the diagnosis of Clostridioides difficile infection},
journal = {Microbiology Spectrum},
year = {2025},
doi = {10.1128/spectrum.03405-24}
}
EUVIMED